History
-
Establishment
Established in August 2024 by the three co-founders of the entity in the UK under the registration number of 15878502, Innovarus is comprised of a team of co founders, each bringing expertise in scientific operations, marketing and distribution, and organisational management, to ensure comprehensive coverage of all critical areas required for the successful development and viability of this venture.
-
Initiatives
The entity’s scientific and administrative initiatives, including chemical operations and market research, started in September 2023, leading to the development of the viable and scalable concept of Octovarus. Significant progress has been achieved on both the scientific and business fronts, effectively de-risking the entity and strengthening the co founders’ confidence to continue advancing its scientific and marketing operations. This progress has also positioned the entity to engage with potential creditors to secure additional resources and accelerate the development process.
-
Experience
Prior to the development of this product, the current team successfully launched the 1-month version of Octreotide, as well as 1 month and 3-month versions of Leuprolide, alongside several other long-acting injectables. These achievements have equipped the team with substantial experience in understanding market dynamics and executing effective marketing strategies for introducing extended versions of an existing medicinal product. This background provides a strong foundation for the development and commercialisation of the current product.